Phase 2 Results of VX-659 and VX-445 Investigational Triple Combination Regimens Published in The New England Journal of Medicine
Vertex Announces Phase 2 Results Assessing VX-659 and VX-445 Triple Combination Regimens in People with Cystic Fibrosis Published in The New England Journal of Medicine
October 18, 2018
We are excited to announce that today, The New England Journal of Medicine has published two articles with results from two Phase 2 studies (as well as in vitro data) of our investigational triple combination regimens, VX-659/tezacaftor/ivacaftor and VX-445/tezacaftor/ivacaftor. Our triple combination regimens are currently in development to evaluate treating the underlying cause of cystic fibrosis (CF) in patients with one copy of the F508del mutation and one minimal function mutation (Min), and in patients with two copies of the F508del mutation. The published data also includes results assessing the once-daily investigational triple combination regimens (VX-659, tezacaftor and VX-561; VX-445, tezacaftor and VX-561) in F508del/Min patients.
Results were published concurrently with presentations at the 32nd Annual North American Cystic Fibrosis Conference (NACFC) in Denver. Phase 3 clinical trial programs assessing both triple combination regimens are currently underway.
“We are thrilled to have two simultaneous publications in The New England Journal of Medicine, a milestone that underscores the innovation that our triple combination regimens potentially represent to those living with CF. We are excited to continue moving these therapies through Phase 3 clinical research trials.” – Reshma Kewalramani, M.D., Executive Vice President and Chief Medical Officer at Vertex.